In this paper, an objective function for training a functional link network to tolerate multiplicative weight noise is presented. Basically, the objective function is similar in form to other regularizer-based functions that consist of a mean square training error term and a regularizer term. Our study shows that under some mild conditions the derived regularizer is essentially the same as a weight decay regularizer. This explains why applying weight decay can also improve the fault-tolerant ability of a radial basis function (RBF) with multiplicative weight noise. In accordance with the objective function, a simple learning algorithm for a functional link network with multiplicative weight noise is derived. Finally, the mean prediction error of the trained network is analyzed. Simulated experiments on two artificial data sets and a real-world application are performed to verify theoretical result.

Download full-text PDF

Source
http://dx.doi.org/10.1109/TNN.2008.2005596DOI Listing

Publication Analysis

Top Keywords

objective function
16
multiplicative weight
16
weight noise
16
prediction error
8
learning algorithm
8
functional link
8
link network
8
weight decay
8
weight
6
objective
4

Similar Publications

Validation of Sleep Measurements of an Actigraphy Watch: Instrument Validation Study.

JMIR Form Res

January 2025

Department of Biomedical Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Background: The iAide2 (Tokai) physical activity monitoring system includes diverse measurements and wireless features useful to researchers. The iAide2's sleep measurement capabilities have not been compared to validated sleep measurement standards in any published work.

Objective: We aimed to assess the iAide2's sleep duration and total sleep time (TST) measurement performance and perform calibration if needed.

View Article and Find Full Text PDF

Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.

Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.

Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.

View Article and Find Full Text PDF

Importance: Intraventricular hemorrhage (IVH) has proven to be a challenging and enduring complication of prematurity. However, its association with neurodevelopment across the spectrum of IVH severity, independent of prematurity, and in the context of contemporary care remains uncertain.

Objective: To evaluate national trends in IVH diagnosis and the association with survival and neurodevelopmental outcomes at 2 years of age.

View Article and Find Full Text PDF

Traumatic brain injury (TBI) and subsequent post-traumatic epilepsy (PTE) often impair daily activities and mental health (MH), which contribute to long-term TBI-related disability. PTE also affects driving capacity, which impacts functional independence, community participation, and satisfaction with life (SWL). However, studies evaluating the collective impact of PTE on multidimensional outcomes are lacking.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the clinical efficacy and safety of minimally invasive hematoma evacuation for the treatment of traumatic intracranial hematoma (TIH).

Methods: Ninety patients diagnosed with traumatic intracerebral hematoma at Shengli Oilfield Central Hospital from August 2019 to September 2023 were selected as the study subjects. The patients were divided into the craniotomy group (C group, n = 45) and the minimally invasive hematoma evacuation group (MIHE group, n = 45).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!